Repsol S.A. (REP)
Deutsche Börse Xetra · Germany · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 28.70 |
|---|---|
| 52-week range | 15.23 – 31.63 |
| Return, 1 month / 3 months | −6.9% / +12.0% |
| Return, 1 year / 3 years | +94.4% / +153.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 46 |
| Volatility (1 year) | 34.2% |
| Worst drawdown (1 year) | -20.5% |
| Average daily value traded | 0.43M EUR |
| Dividend yield | 3.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Repsol is an integrated energy company based in Madrid, Spain. It explores for and produces crude oil and natural gas, refines crude oil into fuels and petrochemical products, and markets petrol, diesel, lubricants and liquefied petroleum gas. Its customers include motorists and businesses served through service stations under the Repsol brand, along with industrial buyers of fuels, chemicals and gas. The company also generates and supplies electricity and develops lower-carbon energy projects.
The shares are listed on the Deutsche Börse Xetra in Germany under the code REP, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Repsol S.A. (REP) trades on the Deutsche Börse Xetra in Germany. It last closed at EUR 28.70 on 27 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 37 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 94.4% and over the last three months it rose 12.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Deutsche Börse Xetra
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 87 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 23.4% | ||
| From 52-week high | -8.9% | ||
| Momentum | 91 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 12.0% | ||
| 6-month return | 39.0% | ||
| 12-month return, skipping the last month | 108.9% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 34.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.5% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.43M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 60 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −1.7% |
|---|---|
| 1 month | −6.9% |
| 3 months | +12.0% |
| 6 months | +39.0% |
| 1 year | +94.4% |
| 3 years | +153.1% |
| 5 years | +242.0% |
Signals
| 50-day / 200-day average | 28.93 / 23.26 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.85 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Jul 2026 | EUR 0.5510 |
| 12 Jan 2026 | EUR 0.5000 |
| 4 Jul 2025 | EUR 0.5000 |
| 10 Jan 2025 | EUR 0.4750 |
| 4 Jul 2024 | EUR 0.5000 |
| 9 Jan 2024 | EUR 0.4000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Deutsche Börse Xetra; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.